English Global
PRESS RELEASE
June 2nd, 2025 | New Delhi
Empowering Public Health Across the African Region
Panacea Biotec Receives cGMP certificate under AMRH and EAEU Program
Panacea Biotec, a global leader in vaccine innovation and high-quality biopharmaceuticals, proudly announces receipt of African Medical Agency Green Book listing, a publicly available registry published by the African Medicines Regulatory Harmonisation (AMRH), that lists human medicinal products which have undergone African continental evaluation and received a positive opinion regarding safety, efficacy, and quality.
We are proud to share that EasySix has been recognised and listed by the Green Book.
EasySix, World’s First Fully-Liquid wP-IPV Based Hexavalent Vaccine, provides safe, effective, and WHO-prequalified immunization against 6 deadly diseases, streamlining vaccination schedules and enhancing national immunization programs. EasySix protects against Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae type b (Hib), and Poliovirus. Panacea Biotec has also received cGMP (current Good Manufacturing Practice) from the Kazakhstan Ministry of Health, under the Eurasian Economic Union (EAEU) harmonization program and cGMP from Philippines.
With this milestone, Panacea Biotec expands its reach across all African and EAEU member states, including Armenia, Belarus, Kyrgyzstan, and Russia, unlocking unified regulatory access and streamlined distribution pathways.
Innovation That Builds Trust
Robust Pipeline:
“Welcoming Strategic Distribution Partners” - Mr. PD Karan
“We are actively seeking new distribution partners across Africa, Uzbekistan, and the EAEU region to support the roll-out of EasySix and our upcoming product pipeline.” mentioned Mr. PD Karan, Vice President at Panacea Biotec.
Join hands with Panacea Biotec - a name synonymous with quality, safety, and innovation in immunization. Together, Let’s Build a Healthier World.
Email us at Contact Us and Select ‘Business Development - Biologicals and Vaccines’
About Panacea Biotec
Panacea Biotec Limited is a leading pharmaceutical and biotechnology company with established research, manufacturing and marketing capabilities.
Panacea Biotec’s wholly-owned subsidiary, Panacea Biotec Pharma Limited has pioneered in the development of innovative fully-liquid combination vaccines that can be stored at 2-8 degree Celsius temperature.
Panacea Biotec has also launched the world's first fully liquid wP-IPV based hexavalent vaccine EasySix (DTwP-HepB-Hib-IPV) in India in March 2017. We have made available over 200 million doses of fully-liquid combination vaccines across the world.
The other key vaccines in portfolio are Easyfive-TT (DTwP-HepB-Hib), EasyFour-TT (DTwP-Hib), IPV based tetravalent vaccine – EasyFour-Pol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Panacea Biotec’s new vaccines in pipeline are Pneumococcal Conjugate Vaccine - NucoVac-11, NuCoVac-13 and Recombinant Tetravalent Dengue Candidate Vaccine - DengiALL and India’s first thiomersal free Td (tetanus and diphtheria – reduced).
For media queries, please contact:
Mr. P. D. Karan
Sr. Vice President - Business Development & Corporate Affairs
Tel: +91-11-41679000 Ext. 1406, 41578080 (Direct)
Mobile: +91 9312693040, +91 9810500539
Email: pdkaran@panaceabiotec.com
Ms. Geetanjali Grover
Sr. Manager - Corporate Communications
Tel: +91-11-41679000 Ext. 1414
Mobile: +91 99100 32288
Email: geetanjaligrover@panaceabiotec.com